机构:[1]Key Laboratory of Medical Electrophysiology of Ministry of Education, Medical Electrophysiology Key Lab of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, 646000, China.[2]Department of General Surgery (Breast Surgery), the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.[3]Department of Cardiology, Peking University First Hospital, Beijing, 100034, China.
This work was supported by the Fund of Sichuan Science
and Technology Program (2022YFS0610), Education Department of Sichuan Province (16ZA0192) and Science and
Technology Strategic Cooperation Project of the Government of Luzhou and Southwest Medical University
(2019LZXNYDF02)
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
无
最新[2023]版:
大类|4 区医学
小类|4 区肿瘤学4 区药学
第一作者:
第一作者机构:[1]Key Laboratory of Medical Electrophysiology of Ministry of Education, Medical Electrophysiology Key Lab of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, 646000, China.
共同第一作者:
通讯作者:
通讯机构:[1]Key Laboratory of Medical Electrophysiology of Ministry of Education, Medical Electrophysiology Key Lab of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, 646000, China.[*1]Key Laboratory of Medical Electrophysiology of Ministry of Education, Medical Electrophysiology Key Lab of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, 646000, China
推荐引用方式(GB/T 7714):
Wang Siqi,Ji Fang,Gao Xiaoli,et al.Tyrosine Kinase Inhibitor Lenvatinib Causes Cardiotoxicity by Inducing Endoplasmic Reticulum Stress and Apoptosis through Activating ATF6, IRE1α and PERK Signaling Pathways[J].Recent Patents On Anti-Cancer Drug Discovery.2024,doi:10.2174/0115748928265981231204044653.
APA:
Wang Siqi,Ji Fang,Gao Xiaoli,Li Zhiyi,Lv Si...&Li Miaoling.(2024).Tyrosine Kinase Inhibitor Lenvatinib Causes Cardiotoxicity by Inducing Endoplasmic Reticulum Stress and Apoptosis through Activating ATF6, IRE1α and PERK Signaling Pathways.Recent Patents On Anti-Cancer Drug Discovery,,
MLA:
Wang Siqi,et al."Tyrosine Kinase Inhibitor Lenvatinib Causes Cardiotoxicity by Inducing Endoplasmic Reticulum Stress and Apoptosis through Activating ATF6, IRE1α and PERK Signaling Pathways".Recent Patents On Anti-Cancer Drug Discovery .(2024)